Novo Cellular Medicine Institute LLP   Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2015
NCT02587715
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Multiple Sclerosis (Phase 2)

Multiple Sclerosis, Relapsing-Remitting (Phase 2)

Sclerosis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2